Needham & Company Reiterates Buy on Akcea Therapeutics (AKCA) Following FDA Approval of Tegsedi
Tweet Send to a Friend
Needham & Company analyst, Chad Messer, reiterated a Buy rating and $45.00 price target on Akcea Therapeutics, Inc. (NASDAQ: AKCA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
